San Diego, CA -- (SBWIRE) -- 01/05/2015 -- An investor, who SOLD shares of Allergan, Inc. (NYSE:AGN) between February 25, 2014 and April 21, 2014, filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between February 25, 2014 and April 21, 2014.

If you SOLD a significant amount of shares of Allergan, Inc. (NYSE:AGN) between February 25, 2014 and April 21, 2014, you have certain options and for certain investors are short and strict deadlines running. Deadline: February 16, 2015. NYSE:AGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

In early February 2014 Valeant began taking steps toward launching a tender offer directly to Allergan's stockholders.

According to the complaint the plaintiff alleges on behalf of those who SOLD shares of Allergan, Inc. (NYSE:AGN) between February 25, 2014 and April 21, 2014, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that in violation of federal securities laws, Valeant tipped Pershing Square regarding Valeant's tender offer and Pershing Square, through its newly formed shell entity PS Fund 1 LLC , began on February 25, 2014 to acquire Allergan, Inc. (NYSE: AGN) stock based upon that inside information.

The plaintiff claims that by the time Pershing Square disclosed PS Fund 1's stake on April 21, 2014, it had already acquired 9.7% of Allergan's outstanding stock, for a total investment at the time of over $3.2 billion without providing Allergan's stockholders and the marketplace any disclosure about Valeant's intention to launch a tender offer for Allergan. Following the announcement the value of Pershing Square's investment in Allergan stock increased by a billion dollars.

The plaintiff says that the defendants profited from their alleged misconduct and are said to realize a profit of approximately $2.5 billion from their investment of less than a year in Allergan partially by taking advantage of insider information.

The plaintiff claims that had Allergan shareholders known the truth they would not have sold their Allergan stock between February 25, 2014 and April 21, 2014.

Those who SOLD shares of Allergan, Inc. (NYSE:AGN) between February 25, 2014 and April 21, 2014have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com